The Ministry of Industry and Information Technology subsidies to 0.55 billion these Chinese medicine varieties have the most opportunity


Release time:

2017-08-29

5 things should be done to upgrade the technology and service guarantee of traditional Chinese medicine industry.

Recently, the Ministry of Industry and Information Technology's ''Notice of the Ministry of Industry and Information Technology on Issuing the 2017 Industrial Transformation and Upgrading (Made in China 2025) Fund (Departmental Budget) Project Guide'' (hereinafter referred to as the Notice) was released, in order to fully implement the China Manufacturing 2025 development strategy and accelerate the supply side Structural reforms, promote industrial transformation and upgrading, and vigorously revitalize the real economy, the Ministry of Industry and Information Technology has decided to organize and implement key projects of funds (departmental budget) for industrial transformation and upgrading (made in China 2025) in 2017.

According to the notice, the state intends to provide financial support for 25 project tasks related to the 2017 Industrial Transformation and Upgrading (Made in China 2025) strategy in the near future.

Among them, there are six items related to medicine-except one for the guarantee of shortage of drugs, the others are related to the traditional Chinese medicine industry, which shows the importance attached to the transformation and upgrading of the traditional Chinese medicine industry.

In terms of the support and subsidy content of traditional Chinese medicine preparations and traditional Chinese medicine alone, the total number of funded projects is about 11, with a planned investment of about 0.55 billion yuan.

The task items and support related to the Chinese medicine industry are notified as follows:

(Note: The information comes from the website of the Ministry of Industry and Information Technology)

Chinese medicine industry favorable policies continue

The state has promoted the development of traditional Chinese medicine to the important position of national strategy.

Since the State Administration of Traditional Chinese Medicine issued the "Outline of Scientific and Technological Innovation in Traditional Chinese Medicine Prevention and Health Care (Treatment of Disease) Services (2013-2020)" on March 25, 2013, it was promulgated by the end of 2016 and officially implemented on July 1. The the People's Republic of China Law on Traditional Chinese Medicine has raised the support for traditional Chinese medicine to a legal level.

According to the author's preliminary incomplete statistics, in just two years, my country's central ministries and commissions and various localities have successively issued more than 50 supporting policy documents for the development of the Chinese medicine industry, including relevant plans and policies for the cultivation and protection of upstream medicinal materials, as well as policies and opinions on the circulation and trade of medicinal materials in the middle reaches.

In mid-June, the Ministry of Science and Technology of the People's Republic of China issued the "Thirteenth Five-Year Plan for Traditional Chinese Medicine Science and Technology Innovation", which clearly stated that during the "Thirteenth Five-Year Plan" period, it will strive to form 3-5 Chinese medicine health product groups with an output value exceeding 1 billion yuan, and internationally renowned brands 1-2.

Recently, the Ministry of Industry and Information Technology issued the ''Notice of the Ministry of Industry and Information Technology on Issuing the 2017 Industrial Transformation and Upgrading (Made in China 2025) Fund (Departmental Budget) Project Guide'', which even proposed specific number of subsidy projects and project standards for the development of traditional Chinese medicine.

These large varieties of traditional Chinese medicine and enterprises may have the most opportunity to obtain financial support.

In the notice of the Ministry of Industry and Information Technology, it is clearly stated that the technical improvement of traditional Chinese medicine varieties is clearly stated that the varieties in the basic medicine catalogue with sales revenue exceeding 0.3 billion will be given priority to financial subsidies for technical improvement, and the top 100 enterprises in the traditional Chinese medicine industry will also be given priority.

According to the above standards, the author selected 19 drugs. The sales revenue of these drugs in 2016 was above 0.3 billion, and they were all varieties in the 2012 edition of the national basic drug catalog.

Among them, oral drugs accounted for the vast majority, with 11, 7 injections and 1 external use.

In terms of enterprises, Tianshili, Buchang and Shenwei all have two products on the list, and these enterprises are not only the top 100 enterprises in China's traditional Chinese medicine industry, but also the top 100 enterprises in China's pharmaceutical industry, and these large enterprises have more opportunities for large projects. it is also a benchmark enterprise for the development of traditional Chinese medicine, and these enterprises have the most opportunity to obtain financial subsidies.

Details of these varieties and enterprises are as follows:

(Note: Data from the annual reports of listed companies, some varieties of data based on sales volume, in order of sales revenue; data for reference)

Chinese medicine drink tablets industry concentration will increase, leading enterprises or further expansion

A few days ago, the Ministry of Industry and Information Technology released the economic indicators of my country's pharmaceutical industry in the first half of 2017. Traditional Chinese medicine decoction pieces are the fastest-growing sub-industry, which is inseparable from the country's strong policy support in recent years.

Speaking of the representative of the Chinese medicine decoction pieces industry, there is no doubt that Kangmei Pharmaceutical, which has the advantages of the development of Chinese medicinal materials and Chinese medicine decoction pieces, has formed advantages in technology and the entire industry chain.

Within 10 days after the release of the pilot liberalization policy of traditional Chinese medicine formula granules in Guangdong Province, Kangmei Pharmaceutical obtained the qualification for the pilot production and sales of traditional Chinese medicine formula granules, and the ability to integrate the industrial chain can be seen, which at the same time opened up a new growth point for the development of its traditional Chinese medicine decoction pieces plate.

Recently, Kangmei Pharmaceutical Co., Ltd. has been listed in Forbes' top 50 listed companies in Asia in 2017 (click to read: 5 pharmaceutical companies have been listed in Forbes' best in Asia), which shows its development potential.

In addition, Kangmei Pharmaceuticals has a Chinese herbal medicine information portal and industry third-party service Chinese medicine trading platform Kangmei Chinese medicine network, has a more solid data information base, but also built a higher barrier, the future sustainable development can be expected.

(Note: Data from the company's annual listing report)